Profile Picture
  • All
  • Search
  • Images
  • Videos
  • Maps
  • News
  • Copilot
  • More
    • Shopping
    • Flights
    • Travel
  • Notebook
  • Top stories
  • Sports
  • U.S.
  • Local
  • World
  • Science
  • Technology
  • Entertainment
  • Business
  • More
    Politics
Order byBest matchMost fresh
  • Any time
    • Past hour
    • Past 24 hours
    • Past 7 days
    • Past 30 days

Pfizer, Valneva Lyme vaccine misses primary endpoint

Digest more
 · 4d
Pfizer Lyme vaccine shows more than 70% efficacy but misses key statistical goal
There hasn't been an approved Lyme disease vaccine for more than 20 years, after GSK pulled its shot because of a lack of demand.

Continue reading

 · 4d · on MSN
Pfizer’s long-awaited Lyme vaccine fails to impress in study
Fierce Biotech · 4d
Pfizer, Valneva blame low Lyme cases for phase 3 vaccine fail but still plan approval push
4d

Pfizer to seek FDA approval for Lyme vaccine as CT report shows ticks are more abundant than ever

The annual tick report shows Lone Star ticks have established populations along Connecticut's shoreline, raising the risk of ...
2d

Lyme disease vaccine shows strong results. How it works.

The first human Lyme disease vaccine was 73% effective against the tick-borne illness, says Pfizer. They still plan to seek ...
16h

Should Pfizer’s (PFE) New Lyme Vaccine and Oncology Wins Reshape Its Post‑COVID Pipeline Story?

In March 2026, Pfizer and partner Valneva reported that their investigational 6‑valent OspA-based Lyme disease vaccine ...
15hon MSN

Lyme vaccine shows strong protection in trials that included New Yorkers

If approved, the Pfizer-Valneva vaccine could become highly sought-after as Lyme disease surges in the Hudson Valley.

Some results have been hidden because they may be inaccessible to you

Show inaccessible results
  • Privacy
  • Terms